
UCB leads the stale scale
Several big groups’ portfolios are ageing, and regulatory action risks blocking their renewal.

Asco 2023 – Enhertu hits with pan approach
Strong data prompt talk of a tumour-agnostic approval, but regulators could prove reluctant in the broad Her2 setting.

Asco 2023 – a role for immuno-oncology in ovarian cancer at last?
Astra’s Duo-O trial suggests that excluding Brca-positive patients could be the key to Imfinzi’s apparent success in ovarian cancer.

Asco 2023 – Novartis’s adjuvant breast cancer win comes with caveats
The Natalee trial hits in all-comers, but an equivocal showing in node-negative patients raises questions about market expansion.

A blockbuster year could be building
If forecasts prove accurate 2023 could be the biggest year for blockbuster launches for some time.